Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: Experience in one centre

Lorenzo Beretta, Monica Caronni, Massimo Raimondi, Alessandra Ponti, Tiziana Viscuso, Laura Origgi, Raffaella Scorza

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Lung involvement constitutes nowadays the major cause of morbidity and mortality in scleroderma patients. Pulmonary fibrosis in systemic sclerosis (SSc) is thought to be the consequence of interstitial inflammation. Early diagnosis and treatment of active alveolitis is essential to prevent the deterioration of pulmonary function, improving outcome in SSc patients. The aim of the study was to investigate the effect of 1-year treatment with oral cyclophosphamide (CYC) on the evolution of interstitial lung disease in scleroderma patients with a diagnosis of active alveolitis. An open-label one-arm monocenteric study was conducted on 33 scleroderma patients with active alveolitis - defined as the presence of areas of 'ground-glass attenuation' on high-resolution computed tomography and a recent deterioration in lung function-treated with oral CYC 2 mg kg-1 day-1 for 1 year and medium-low dose steroids (prednisone 25 mg for 3 months and then tapered to 5 mg/day). Results showed that diffusing capacity for carbon monoxide (DLco) values remained stable after 6 months of treatment and significantly increased after 12 months (2.06±1.38, 2.21±1.62 and 2.39±1.64 mmol/min/kPa, at baseline/6/12 months, respectively; p

Original languageEnglish
Pages (from-to)168-172
Number of pages5
JournalClinical Rheumatology
Volume26
Issue number2
DOIs
Publication statusPublished - Feb 2007

Fingerprint

Pulmonary Fibrosis
Cyclophosphamide
Lung
Systemic Scleroderma
Interstitial Lung Diseases
Carbon Monoxide
Prednisone
Glass
Early Diagnosis
Therapeutics
Steroids
Tomography
Inflammation
Morbidity
Mortality

Keywords

  • Cylophosphamide
  • Fibrosingal veolitis
  • HRCT
  • Systemics clerosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis : Experience in one centre. / Beretta, Lorenzo; Caronni, Monica; Raimondi, Massimo; Ponti, Alessandra; Viscuso, Tiziana; Origgi, Laura; Scorza, Raffaella.

In: Clinical Rheumatology, Vol. 26, No. 2, 02.2007, p. 168-172.

Research output: Contribution to journalArticle

Beretta, Lorenzo ; Caronni, Monica ; Raimondi, Massimo ; Ponti, Alessandra ; Viscuso, Tiziana ; Origgi, Laura ; Scorza, Raffaella. / Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis : Experience in one centre. In: Clinical Rheumatology. 2007 ; Vol. 26, No. 2. pp. 168-172.
@article{fc7fd956d50d4552b15aff8873d7d2cb,
title = "Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: Experience in one centre",
abstract = "Lung involvement constitutes nowadays the major cause of morbidity and mortality in scleroderma patients. Pulmonary fibrosis in systemic sclerosis (SSc) is thought to be the consequence of interstitial inflammation. Early diagnosis and treatment of active alveolitis is essential to prevent the deterioration of pulmonary function, improving outcome in SSc patients. The aim of the study was to investigate the effect of 1-year treatment with oral cyclophosphamide (CYC) on the evolution of interstitial lung disease in scleroderma patients with a diagnosis of active alveolitis. An open-label one-arm monocenteric study was conducted on 33 scleroderma patients with active alveolitis - defined as the presence of areas of 'ground-glass attenuation' on high-resolution computed tomography and a recent deterioration in lung function-treated with oral CYC 2 mg kg-1 day-1 for 1 year and medium-low dose steroids (prednisone 25 mg for 3 months and then tapered to 5 mg/day). Results showed that diffusing capacity for carbon monoxide (DLco) values remained stable after 6 months of treatment and significantly increased after 12 months (2.06±1.38, 2.21±1.62 and 2.39±1.64 mmol/min/kPa, at baseline/6/12 months, respectively; p",
keywords = "Cylophosphamide, Fibrosingal veolitis, HRCT, Systemics clerosis",
author = "Lorenzo Beretta and Monica Caronni and Massimo Raimondi and Alessandra Ponti and Tiziana Viscuso and Laura Origgi and Raffaella Scorza",
year = "2007",
month = "2",
doi = "10.1007/s10067-006-0254-x",
language = "English",
volume = "26",
pages = "168--172",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "2",

}

TY - JOUR

T1 - Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis

T2 - Experience in one centre

AU - Beretta, Lorenzo

AU - Caronni, Monica

AU - Raimondi, Massimo

AU - Ponti, Alessandra

AU - Viscuso, Tiziana

AU - Origgi, Laura

AU - Scorza, Raffaella

PY - 2007/2

Y1 - 2007/2

N2 - Lung involvement constitutes nowadays the major cause of morbidity and mortality in scleroderma patients. Pulmonary fibrosis in systemic sclerosis (SSc) is thought to be the consequence of interstitial inflammation. Early diagnosis and treatment of active alveolitis is essential to prevent the deterioration of pulmonary function, improving outcome in SSc patients. The aim of the study was to investigate the effect of 1-year treatment with oral cyclophosphamide (CYC) on the evolution of interstitial lung disease in scleroderma patients with a diagnosis of active alveolitis. An open-label one-arm monocenteric study was conducted on 33 scleroderma patients with active alveolitis - defined as the presence of areas of 'ground-glass attenuation' on high-resolution computed tomography and a recent deterioration in lung function-treated with oral CYC 2 mg kg-1 day-1 for 1 year and medium-low dose steroids (prednisone 25 mg for 3 months and then tapered to 5 mg/day). Results showed that diffusing capacity for carbon monoxide (DLco) values remained stable after 6 months of treatment and significantly increased after 12 months (2.06±1.38, 2.21±1.62 and 2.39±1.64 mmol/min/kPa, at baseline/6/12 months, respectively; p

AB - Lung involvement constitutes nowadays the major cause of morbidity and mortality in scleroderma patients. Pulmonary fibrosis in systemic sclerosis (SSc) is thought to be the consequence of interstitial inflammation. Early diagnosis and treatment of active alveolitis is essential to prevent the deterioration of pulmonary function, improving outcome in SSc patients. The aim of the study was to investigate the effect of 1-year treatment with oral cyclophosphamide (CYC) on the evolution of interstitial lung disease in scleroderma patients with a diagnosis of active alveolitis. An open-label one-arm monocenteric study was conducted on 33 scleroderma patients with active alveolitis - defined as the presence of areas of 'ground-glass attenuation' on high-resolution computed tomography and a recent deterioration in lung function-treated with oral CYC 2 mg kg-1 day-1 for 1 year and medium-low dose steroids (prednisone 25 mg for 3 months and then tapered to 5 mg/day). Results showed that diffusing capacity for carbon monoxide (DLco) values remained stable after 6 months of treatment and significantly increased after 12 months (2.06±1.38, 2.21±1.62 and 2.39±1.64 mmol/min/kPa, at baseline/6/12 months, respectively; p

KW - Cylophosphamide

KW - Fibrosingal veolitis

KW - HRCT

KW - Systemics clerosis

UR - http://www.scopus.com/inward/record.url?scp=33845867399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845867399&partnerID=8YFLogxK

U2 - 10.1007/s10067-006-0254-x

DO - 10.1007/s10067-006-0254-x

M3 - Article

C2 - 16614793

AN - SCOPUS:33845867399

VL - 26

SP - 168

EP - 172

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 2

ER -